Peripheral blood progenitor cells (PBPC) can be mobilized by chemotherapy, cytokines, or the combination of both. Recently, data from two non-randomized studies were published, showing an advantage for a combination of rhG-CSF plus rhEpo compared to rhG-CSF alone in mobilization of PBPC. To address this question we initiated a prospective, randomized trial in patients with breast cancer. Thirty (28 female, two male) of 32 randomized patients were evaluable. After primary surgery, therapy consisted of two cycles of VIP-E chemotherapy followed by high-dose (HD) chemotherapy with VIC. Mobilization and harvest of PBPC followed cycle 2. Group A received 5 g rhG-CSF/kg body weight (bw) plus 150 IU rhEpo/kg bw. Group B was treated with 5 g rhG-CSF/kg bw from d1 until end of harvest. In the peripheral blood CD34 + cells as well as colony-forming units (CFU) started to rise on d8 with a peak on d10, followed by a decrease. No significant differences were observed between the groups. Furthermore, there was no significant difference with regard to MNC, CD34 + cells BFU-E and CFU-GM in apheresis products. Transplantation of Ͼ1 × 10 6 CD34 + cells/kg bw after HD chemotherapy resulted in normal hematological recovery of all patients. No differences were observed in time to neutrophil or platelet recovery and need for blood product support. In this study addition of rhEpo to our standard mobilization chemotherapy did not result in improved mobilization of PBPC or in clinical benefits after HD chemotherapy. Keywords: PBPC mobilization; cytokines; erythropoietin; rhG-CSF; breast cancer Bone marrow toxicity has been the limiting factor for doseintensity of chemotherapy in the past. High-dose (HD) chemotherapy with subsequent transplantation of autologous hematopoietic progenitor cells has offered a new therapeutic modality to increase dose-intensity compared to stan-
dard-dose chemotherapy which has been increasingly used for different kinds of cancer in recent years. Several publications indicate a possible survival benefit of HD chemotherapy compared to standard-dose chemotherapy in patients with breast cancer. [1] [2] [3] The observation that it is possible to mobilize hematopoietic progenitor cells from bone marrow into peripheral blood using chemotherapy, recombinant human (rh) cytokines or the combination of both has led to their preferred use for transplantation. Peripheral blood progenitor cell (PBPC) transplantation is associated with less morbidity and more rapid recovery of neutrophils and platelets. 4 A reduction of the need for antibiotics and blood products has resulted in a cost reduction due to a shortened period of hospitalization. 5 Furthermore, there have been indications that the use of PBPC leads to a lower amount of contaminating tumor cells in the graft in comparison to bone marrow. 6, 7 The optimal mobilization protocol, however, has not yet been determined. Different chemotherapy regimens and cytokines including rhG-CSF, rhGM-CSF, rhIL-3, rhSCF, FLT3-ligand, rhMGDF as well as different cytokine combinations have been investigated in healthy individuals and in cancer patients for their potential to mobilize PBPC into the peripheral blood. 4, [8] [9] [10] [11] [12] [13] [14] [15] Erythropoietin (rhEpo) has previously been shown to have effects in vivo on circulating PBPC and to increase peripheral blood colony-forming cell numbers but not of cells capable of long-term hematopoiesis. 16, 17 Recently, there have been two non-randomized studies indicating an advantage for PBPC mobilization of the combination of rhEpo and rhG-CSF over rhG-CSF alone. 18, 19 In order to further address this question we initiated a prospective randomized trial in patients with newly diagnosed stage II-IV breast cancer.
Patients, materials and methods

Patients
Eligible were patients with stage II or stage III adeno-carcinoma of the breast with 10 or more involved lymph nodes as well as stage IV patients who were newly diagnosed or had not received chemotherapy for metastatic disease and patients who had not been treated with anthracyclin containing adjuvant chemotherapy for more than 1 year before entering the study. Exclusion criteria were a Karnofsky per- (1-h infusion, d1 and d22), and epirubicine 50 mg/m 2 (bolus injection, d1 and d22). Both groups received rhG-CSF at 5 g/kg bw after the first cycle of chemotherapy to accelerate hematological recovery. Mobilization and harvest of PBPC followed the second cycle. Group A received 5 g rhG-CSF/kg bw (Neupogen, Filgrastim; Amgen, Munich, Germany) plus 150 IU rhEpo/kg bw (Erypo; CILAG, Sulzbach, Germany), group B was treated with rhG-CSF at a dose of 5 g/kg bw. Cytokines were given subcutaneously from d1 after end of chemotherapy until the end of harvest. Patients were treated as out-patients. WBC, platelet counts as well as hemoglobin (Hb) were monitored on d6-8, d10, d11 and d12 post chemotherapy. The content of CD34 + cells in the PB was measured d6-8 as well as on d10, d11 and d12 after mobilization chemotherapy. Leukapheresis was started at WBC counts above 10 000/l in the peripheral blood (PB) 2-4 h after the last injection of cytokines. Apheresis was performed using a CS-3000 Plus blood cell separator (Baxter, Unterschleißheim, Germany). In the majority of patients 16-gauge needles for venous access through cubital or antecubital veins were used. Apheresis procedures were performed using a flow rate of 40-85 ml/min. Target cell dose was 2 × 10 6 CD34 + cells/kg bw. Collection and freezing of PBPC was performed as described elsewhere. + cells/kg bw were transplanted on day 0. Intravenous rhG-CSF administration at a dose of 5 g/kg bw was started on day +1 and continued until neutrophil recovery Ͼ1500/l or a WBC count of Ͼ5000/l for 2 consecutive days. Blood products were substituted if Hb levels were Ͻ8.0 g/dl or at platelet counts Ͻ20 000/l.
Immunophenotypic analysis of blood progenitor cells
The total number of MNC in leukapheresis products was evaluated. Differential blood counts were performed at a 1:10 dilution using a Coulter counter (Coulter, Krefeld, Germany). The content of CD34 + cells in the PB was monitored on d−1 before chemotherapy and on d10, d11 and d12 after the second chemotherapy. Additionally, in the first 15 randomized patients (group A, n = 8, group B, n = 7) CD34 + cells were measured on d6 to d8. Furthermore, MNC and CD34
+ cells in apheresis products were analyzed. Flow cytometry was performed using a FACScan analyser (Becton Dickinson, Heidelberg, Germany), equipped with a filter set for FITC-PE dual-color fluorescence, as described previously. 20 Data acquisition was performed with FACScan Lysis II research software and each measurement included 10 000 events.
Colony assays
Clonogenic assays for multi-lineage (CFU-GEMM), erythroid (BFU-E) and myeloid (CFU-GM) progenitors were performed in duplicates on d10, d11 and d12 after the second VIP-E chemotherapy from peripheral blood and of samples of the first apheresis product. Formation of colonies were scored on day 14 after seeding, as described previously. 20 
Statistics
The study was designed to detect a difference between the two treatment arms with a power of 80% and ␣ Ͻ 0.05, if the yield of mobilized stem cells would be increased by a factor of 2. Results are expressed as the median and range, except when stated otherwise. Comparisons among groups were made using the unpaired t test (GraphPad, San Diego, CA, USA). Values shown are median and range. MNC = mononuclear cells; bw = body weight; CFU-GM = colony-forming unit granulocyte-macrophage; BFU-E = burst-forming unit erythroid; CFU-GEMM = colony-forming unit granulocyte, erythrocyte, monocyte, megakaryocyte.
Only results of the first apheresis products are shown, as the majority of patients underwent only one apheresis procedure. P values Ͻ0.05 were considered significant; NS ϭ not significant.
Results
Patients' characteristics
The clinical characteristics of both patient groups who entered the study are shown in Table 1 . Two patients in both groups had prior chemotherapy which consisted of five to six cycles of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) in three and one cycle of EC (epirubicine and cyclophosphamide) in one of them. One patient had received prior local irradiation to the breast. In all pretreated patients prior therapy had ended Ͼ12 months before entry into this study.
Non-hematological side-effects of mobilization
Mobilization chemotherapy, cytokine priming as well as apheresis procedures were not accompanied by major toxicity defined by уWHO grade II in either group.
Peripheral blood counts during mobilization
WBC and platelet counts as well as Hb values after the second VIP-E chemotherapy did not show a significant difference on any day between groups A and B, respectively (data not shown).
Mobilization of PBPC
Measurement of CD34
+ cells in peripheral blood on days 6, 7 and 8 after the second VIP-E chemotherapy was performed in the first 15 randomized patients (group A, n = 8; group B, n = 7). However, due to very low levels of CD34 + cells and the lack of a difference between both groups (data not shown) determination during these days was stopped thereafter. Median values of circulating CD34 + cells in PB at different time points are shown in Table 2 . No significant difference could be found at any time point. Maximum values for CD34 + in group A were reached between d10 and d11 (median d10.4) compared to d10.6 in group B (range d10-d12). There was no significant difference in PBPC mobilization between patients in adjuvant situation and those with metastatic disease in either group, respectively (data not shown). A significantly better mobilisation of CFU-GEMM in group B could be detected on d11. However, medians of CFU-GM, BFU-E on days 10 to 12, and CFU-GEMM on days 10 and 12 after mobilization chemotherapy did not show significant differences between both groups (data not shown).
Apheresis characteristics
Harvest of PBPC was started between d10 and d12 after the end of chemotherapy (median group A, d10; group B, + cells, MNC, as well as values for CFU-GM, BFU-E and CFU-GEMM in apheresis products did not differ significantly (Table 3) .
Transplantation
All mobilized patients except one in group A underwent autologous transplantation following HD chemotherapy. The main non-hematological side-effects of HD chemotherapy were fever, partly due to infection, and stomatitis. Furthermore, some patients suffered from nausea and diarrhea.
Follow-up
All patients recovered normal sustained hematopoiesis and no late graft failure was observed. Median follow-up in patients treated adjuvantly is at 31+ months in both groups (range group A, 22+ to 41+ months; group B, 12+ to 41+ months). In patients with metastatic disease follow-up in group A is at a median of 27 months (range 17-40 months) and 12 months in group B (range 8-40 months), respectively. Twenty-one of 30 transplanted patients are alive. All nine patients who died had progressive disease (three in either group A or B with metastatic disease; one patient in group A and two patients in group B, all in adjuvant situation).
Discussion
Transplantation of autologous hematopoietic progenitor cells after HD chemotherapy to ameliorate hematological toxicity has been applied for various malignancies. 3, 14, 21, 22 The use of mobilized PBPC has been shown to result in a faster engraftment after transplantation and may have the advantage of a lower tumor cell content compared to BM. Different approaches using chemotherapy or cytokines on their own or in different combinations have been used. However, the optimal mobilization protocol has not yet been determined. The best documented cytokines for mobilization to date are rhG-CSF and rhGM-CSF. 4, 10, 14 Erythropoietin has been shown in vitro to significantly increase numbers of BFU-E and CFU-GEMM in patients with anemia of chronic renal failure. 16 In man rhEpo alone for mobilization did not produce the same effects in a cohort of untreated lymphoma patients or in patients with different cancers. 17, 23 Recently, two non-randomized retrospective studies were published indicating a superior effect of the addition of rhEpo to rhG-CSF compared to rhG-CSF alone for PBPC mobilization. 18, 19 In order to further investigate the clinical usefulness of the combination of rhEpo and rhG-CSF for PBPC mobilization this randomized prospective study using these two cytokines in a cohort of chemotherapy naive breast cancer patients as well as some patients after previous adjuvant chemotherapy was initiated.
Mobilization chemotherapy with consecutive cytokine administration and PBPC harvest were well tolerated in both groups. The numbers of PBPC mobilized in our study were statistically not different. PBPC numbers were higher in both groups than those published by Olivieri et al 18 although the CFU-GM numbers in both groups did not exceed their results. Our patients did not show a significant difference with regard to MNC. In contrast to data published by Pierelli et al 19 as well as by Olivieri 18 we did not observe a significantly higher mobilization of CD34 + cells, BFU-E and CFU-GM with the addition of rhEpo. However, numbers of CFU-GEMM on day 11 after mobilization chemotherapy were significantly higher in patients treated with rhG-CSF only. It was possible to harvest enough PBPC for transplantation in all of our patients. Non-hematological toxicity of high-dose chemotherapy was similar in both groups. Kessinger et al 17 reported a median WBC recovery Ͼ500/l on day 16 after HD chemotherapy which is later than in patients of both our groups. This is most likely due to the use of rhEpo alone for mobilization compared to our patients who received chemotherapy and rhG-CSF in addition. Median survival in our patients did not differ significantly between patients in group A and B, respectively.
In conclusion, this prospective randomized study clearly demonstrated that the addition of rhEpo to rhG-CSF did not increase the efficacy of mobilization of hematopoietic progenitor cells in a homogenous group of patients nor did it improve the clinical outcome. Studies investigating the benefit of new cytokines for PBPC mobilization are warranted.
